United States Biotechnology & Medical Research

Q32 Bio Inc (QTTB)

Track

Track

Q32 Bio Inc. experienced three notable insider sales on August 25, 2026, involving the CEO, CFO, and Chief Scientific Officer. These transactions occurred shortly after the company's latest earnings report, which showed a positive EPS surprise. The stock has seen a 38.5% price increase over the past ninety days.
Ticker: QTTB Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Q32 Bio Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
1.0
Violette Shelia M. Chief Scientific Officer Officer
Transaction date
Sale
Price
165.63
Quantity 15,323 +21.4%
Value US$4,062,743
1.4
Morrison Jodie Pope CEO Executive Director
Transaction date
Sale
Price
254.91
Quantity 2,460 -31.2%
Value US$1,160,542
2.3
Kalowski Lee CFO and President Officer
Transaction date
Sale
Price
474.14
Quantity 97,264 -15.0%
Value US$1,461,918
Xu Diyong Non-Executive Director Large shareholder
Transaction date
Purchase
Price
8.00
Quantity 625,000 +inf%
Value US$5,000,000
Xu Diyong Non-Executive Director Large shareholder
Transaction date
Purchase
Price
8.00
Quantity 1,250,000 +55.5%
Value US$10,000,000
2.6
ORBIMED ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
8.00
Quantity 625,000 +inf%
Value US$5,000,000
2.6
ORBIMED ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
8.00
Quantity 1,250,000 +55.5%
Value US$10,000,000
2.3
Kalowski Lee CFO and President Officer
Transaction date
Sale
Price
4.51
Quantity 3,995 -10.0%
Value US$18,035
1.0
Violette Shelia M. Chief Scientific Officer Officer
Transaction date
Sale
Price
4.51
Quantity 2,815 -4.8%
Value US$12,708
1.4
Morrison Jodie Pope CEO Executive Director
Transaction date
Sale
Price
4.51
Quantity 9,896 -10.0%
Value US$44,675
2.3
Kalowski Lee CFO and President Officer
Transaction date
Sale
Price
3.46
Quantity 9,072 -18.5%
Value US$31,395
1.4
Morrison Jodie Pope CEO Executive Director
Transaction date
Sale
Price
3.46
Quantity 22,506 -18.5%
Value US$77,871
1.4
JODIE MORRISON Officer; Director Executive Director
Transaction date
Proposed sale
Price
3.46
Quantity 22,506
Value US$77,871
2.3
LEE KALOWSKI Officer Officer
Transaction date
Proposed sale
Price
3.46
Quantity 9,072
Value US$31,395
1.4
Morrison Jodie Pope CEO Executive Director
Transaction date
Sale
Price
1.80
Quantity 10,494 -8.0%
Value US$18,900
2.3
Kalowski Lee CFO and President Officer
Transaction date
Sale
Price
1.80
Quantity 4,240 -8.0%
Value US$7,636
1.0
Violette Shelia M. Chief Scientific Officer Officer
Transaction date
Sale
Price
1.80
Quantity 2,990 -4.9%
Value US$5,385
TZIANABOS ARTHUR Non-Executive Director
Transaction date
Sale
Price
24.20
Quantity 265 -3.2%
Value US$6,413
Michaud Charles Jr See Remarks Officer
Transaction date
Planned sale
Price
24.20
Quantity 75 -7.5%
Value US$1,815
Alloway Paul See Remarks Officer
Transaction date
Planned sale
Price
24.21
Quantity 268 -9.4%
Value US$6,488
TZIANABOS ARTHUR Non-Executive Director
Transaction date
Planned sale
Price
0.57
Quantity 13,037 -9.2%
Value US$7,445
Michaud Charles Jr See Remarks Officer
Transaction date
Planned sale
Price
0.57
Quantity 1,708 -12.8%
Value US$975
Alloway Paul See Remarks Officer
Transaction date
Planned sale
Price
0.57
Quantity 7,280 -20.6%
Value US$4,120
Seymour Albert See Remarks Executive Director
Transaction date
Planned sale
Price
1.15
Quantity 1,448 -1.0%
Value US$1,665
1.4
Jordan Julie Chief Medical Officer Officer
Transaction date
Sale
Price
1.39
Quantity 1,308 -14.9%
Value US$1,818
1.4
Jordan Julie Chief Medical Officer Officer
Transaction date
Planned sale
Price
1.39
Quantity 109 -2.6%
Value US$152
1.4
Jordan Julie Chief Medical Officer Officer
Transaction date
Planned sale
Price
1.39
Quantity 436 -10.1%
Value US$606
1.4
Jordan Julie Chief Medical Officer Officer
Transaction date
Planned sale
Price
1.31
Quantity 99 -3.5%
Value US$130
Alloway Paul See Remarks Officer
Transaction date
Planned sale
Price
1.45
Quantity 10,965 -39.6%
Value US$15,863
TZIANABOS ARTHUR Non-Executive Director
Transaction date
Planned sale
Price
1.39
Quantity 10,616 -8.9%
Value US$14,762
Alloway Paul See Remarks Officer
Transaction date
Planned sale
Price
1.39
Quantity 3,090 -13.3%
Value US$4,296
Blum Michael Lee Chief Commercial Officer Officer
Transaction date
Planned sale
Price
1.39
Quantity 2,454 -15.3%
Value US$3,412
Smith W Bradford See Remarks Officer
Transaction date
Planned sale
Price
1.39
Quantity 3,729 -20.8%
Value US$5,188
Seymour Albert See Remarks Executive Director
Transaction date
Planned sale
Price
1.39
Quantity 3,620 -2.5%
Value US$5,033
Cohn Gabriel Chief Medical Officer Officer
Transaction date
Planned sale
Price
3.78
Quantity 1,661 -38.7%
Value US$6,279
Smith W Bradford CFO & Treasurer Officer
Transaction date
Planned sale
Price
3.78
Quantity 2,182 -33.1%
Value US$8,248
Seymour Albert Chief Scientific Officer Officer
Transaction date
Planned sale
Price
3.78
Quantity 1,661 -1.2%
Value US$6,279
TZIANABOS ARTHUR President & CEO Executive Director
Transaction date
Planned sale
Price
3.78
Quantity 5,354 -5.9%
Value US$20,239
2.9
Kelly Timothy P Chief Operating Officer Officer
Transaction date
Planned sale
Price
3.78
Quantity 1,406 -38.7%
Value US$5,315
Smith W Bradford CFO & Treasurer Officer
Transaction date
Planned sale
Price
14.25
Quantity 13,500 -100.0%
Value US$192,425
2.9
Kelly Timothy P See Remarks Officer
Transaction date
Planned sale
Price
13.00
Quantity 500 -100.0%
Value US$6,500
2.9
Kelly Timothy P See Remarks Officer
Transaction date
Planned sale
Price
12.37
Quantity 4,000 -100.0%
Value US$49,460
2.9
Kelly Timothy P See Remarks Officer
Transaction date
Planned sale
Price
13.00
Quantity 500 -100.0%
Value US$6,500
Seymour Albert Chief Scientific Officer Officer
Transaction date
Planned sale
Price
12.05
Quantity 5,103 -3.8%
Value US$61,469
Seymour Albert Chief Scientific Officer Officer
Transaction date
Planned sale
Price
12.06
Quantity 9,897 -6.9%
Value US$119,395
Seymour Albert Chief Scientific Officer Officer
Transaction date
Planned sale
Price
11.44
Quantity 10,000 -6.5%
Value US$114,422
2.9
Kelly Timothy P See Remarks Officer
Transaction date
Planned sale
Price
11.50
Quantity 4,000 -100.0%
Value US$45,983
4.0
PARMAR KUSH Non-Executive Director
Transaction date
Sale
Price
12.82
Quantity 20,000 -9.9%
Value US$256,400
3.6
5AM Ventures IV, L.P. Large shareholder
Transaction date
Sale
Price
12.82
Quantity 20,000 -9.9%
Value US$256,400
4.0
PARMAR KUSH Non-Executive Director
Transaction date
Sale
Price
12.82
Quantity 480,000 -9.9%
Value US$6,153,600
3.6
5AM Ventures IV, L.P. Large shareholder
Transaction date
Sale
Price
12.82
Quantity 480,000 -9.9%
Value US$6,153,600
3.6
5AM Ventures IV, L.P. Large shareholder
Transaction date
Sale
Price
11.88
Quantity 13,703 -6.4%
Value US$162,792
3.6
5AM Ventures IV, L.P. Large shareholder
Transaction date
Sale
Price
13.06
Quantity 6,297 -2.8%
Value US$82,244
3.6
5AM Ventures IV, L.P. Large shareholder
Transaction date
Sale
Price
11.88
Quantity 328,862 -6.4%
Value US$3,906,881
4.0
PARMAR KUSH Non-Executive Director
Transaction date
Sale
Price
11.88
Quantity 13,703 -6.4%
Value US$162,792
4.0
PARMAR KUSH Non-Executive Director
Transaction date
Sale
Price
13.06
Quantity 6,297 -2.8%
Value US$82,244
4.0
PARMAR KUSH Non-Executive Director
Transaction date
Sale
Price
11.88
Quantity 328,862 -6.4%
Value US$3,906,881
3.6
5AM Ventures IV, L.P. Large shareholder
Transaction date
Sale
Price
13.06
Quantity 151,138 -2.8%
Value US$1,973,998
4.0
PARMAR KUSH Non-Executive Director
Transaction date
Sale
Price
13.06
Quantity 151,138 -2.8%
Value US$1,973,998
2.9
Kelly Timothy P See Remarks Officer
Transaction date
Planned sale
Price
13.01
Quantity 1,315 -100.0%
Value US$17,109
TZIANABOS ARTHUR President & CEO Executive Director
Transaction date
Planned sale
Price
16.16
Quantity 12,500 -13.9%
Value US$202,021
Smith W Bradford CFO, Treasurer & Secretary
Transaction date
Planned sale
Price
16.16
Quantity 12,000 -100.0%
Value US$193,866
2.8
Flynn James E Large shareholder
Transaction date
Sale
Price
15.45
Quantity 509,970 -100.0%
Value US$7,879,036
2.8
Flynn James E Large shareholder
Transaction date
Sale
Price
15.45
Quantity 8,857 -1.7%
Value US$136,808
2.8
Flynn James E Large shareholder
Transaction date
Sale
Price
15.51
Quantity 65,891 -11.3%
Value US$1,021,936
2.8
Flynn James E Large shareholder
Transaction date
Sale
Price
15.77
Quantity 193,359 -24.9%
Value US$3,049,600
2.8
Flynn James E Large shareholder
Transaction date
Sale
Price
15.69
Quantity 380,256 -32.8%
Value US$5,965,000
Smith W Bradford CFO, Treasurer & Secretary
Transaction date
Planned sale
Price
20.50
Quantity 6,000 -100.0%
Value US$122,984
Seymour Albert Chief Scientific Officer
Transaction date
Planned sale
Price
20.50
Quantity 9,133 -5.6%
Value US$187,216
TZIANABOS ARTHUR President & CEO Executive Director
Transaction date
Planned sale
Price
20.50
Quantity 12,500 -12.2%
Value US$256,191
Flynn James E Large shareholder
Transaction date
Sale
Price
21.95
Quantity 151,233 -7.9%
Value US$3,319,579
Flynn James E Large shareholder
Transaction date
Sale
Price
21.95
Quantity 198,767 -7.9%
Value US$4,362,956
Flynn James E Large shareholder
Transaction date
Sale
Price
21.83
Quantity 56,595 -2.9%
Value US$1,235,435
Flynn James E Large shareholder
Transaction date
Sale
Price
21.83
Quantity 74,384 -2.9%
Value US$1,623,758
Flynn James E Large shareholder
Transaction date
Sale
Price
21.50
Quantity 9,130 -0.5%
Value US$196,297
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-27 2026-08-25 S Sale
1.0
Violette Shelia M.

Chief Scientific Officer

Officer
15,323 +21.4%
165.63
US$4,062,743 		15,323 +21.4% 165.63 US$4,062,743
2026-08-27 2026-08-25 S Sale
1.4
Morrison Jodie Pope

CEO

Executive Director
2,460 -31.2%
254.91
US$1,160,542 		2,460 -31.2% 254.91 US$1,160,542
2026-08-27 2026-08-25 S Sale
2.3
Kalowski Lee

CFO and President

Officer
97,264 -15.0%
474.14
US$1,461,918 		97,264 -15.0% 474.14 US$1,461,918
2026-06-01 2026-05-28 B Purchase
Xu Diyong
Non-Executive Director Large shareholder
625,000 +inf%
8.00
US$5,000,000 		625,000 +inf% 8.00 US$5,000,000
2026-06-01 2026-05-28 B Purchase
Xu Diyong
Non-Executive Director Large shareholder
1,250,000 +55.5%
8.00
US$10,000,000 		1,250,000 +55.5% 8.00 US$10,000,000
2026-06-01 2026-05-28 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
625,000 +inf%
8.00
US$5,000,000 		625,000 +inf% 8.00 US$5,000,000
2026-06-01 2026-05-28 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
1,250,000 +55.5%
8.00
US$10,000,000 		1,250,000 +55.5% 8.00 US$10,000,000
2026-02-27 2026-02-25 S Sale
2.3
Kalowski Lee

CFO and President

Officer
3,995 -10.0%
4.51
US$18,035 		3,995 -10.0% 4.51 US$18,035
2026-02-27 2026-02-25 S Sale
1.0
Violette Shelia M.

Chief Scientific Officer

Officer
2,815 -4.8%
4.51
US$12,708 		2,815 -4.8% 4.51 US$12,708
2026-02-27 2026-02-25 S Sale
1.4
Morrison Jodie Pope

CEO

Executive Director
9,896 -10.0%
4.51
US$44,675 		9,896 -10.0% 4.51 US$44,675
2025-12-04 2025-12-02 S Sale
2.3
Kalowski Lee

CFO and President

Officer
9,072 -18.5%
3.46
US$31,395 		9,072 -18.5% 3.46 US$31,395
2025-12-04 2025-12-02 S Sale
1.4
Morrison Jodie Pope

CEO

Executive Director
22,506 -18.5%
3.46
US$77,871 		22,506 -18.5% 3.46 US$77,871
2025-12-02 2025-12-02 PrS Proposed sale
1.4
JODIE MORRISON

Officer; Director

Executive Director
22,506
3.46
US$77,871 		22,506 3.46 US$77,871
2025-12-02 2025-12-02 PrS Proposed sale
2.3
LEE KALOWSKI

Officer

Officer
9,072
3.46
US$31,395 		9,072 3.46 US$31,395
2025-08-28 2025-08-26 S Sale
1.4
Morrison Jodie Pope

CEO

Executive Director
10,494 -8.0%
1.80
US$18,900 		10,494 -8.0% 1.80 US$18,900
2025-08-28 2025-08-26 S Sale
2.3
Kalowski Lee

CFO and President

Officer
4,240 -8.0%
1.80
US$7,636 		4,240 -8.0% 1.80 US$7,636
2025-08-28 2025-08-26 S Sale
1.0
Violette Shelia M.

Chief Scientific Officer

Officer
2,990 -4.9%
1.80
US$5,385 		2,990 -4.9% 1.80 US$5,385
2024-08-14 2024-03-25 S Sale
TZIANABOS ARTHUR
Non-Executive Director
265 -3.2%
24.20
US$6,413 		265 -3.2% 24.20 US$6,413
2024-04-23 2024-03-25 PlS Planned sale
Michaud Charles Jr

See Remarks

Officer
75 -7.5%
24.20
US$1,815 		75 -7.5% 24.20 US$1,815
2024-04-23 2024-03-25 PlS Planned sale
Alloway Paul

See Remarks

Officer
268 -9.4%
24.21
US$6,488 		268 -9.4% 24.21 US$6,488
2024-02-15 2024-01-09 PlS Planned sale
TZIANABOS ARTHUR
Non-Executive Director
13,037 -9.2%
0.57
US$7,445 		13,037 -9.2% 0.57 US$7,445
2024-01-05 2024-01-03 PlS Planned sale
Michaud Charles Jr

See Remarks

Officer
1,708 -12.8%
0.57
US$975 		1,708 -12.8% 0.57 US$975
2024-01-05 2024-01-03 PlS Planned sale
Alloway Paul

See Remarks

Officer
7,280 -20.6%
0.57
US$4,120 		7,280 -20.6% 0.57 US$4,120
2023-09-08 2023-09-06 PlS Planned sale
Seymour Albert

See Remarks

Executive Director
1,448 -1.0%
1.15
US$1,665 		1,448 -1.0% 1.15 US$1,665
2023-08-07 2023-08-03 S Sale
1.4
Jordan Julie

Chief Medical Officer

Officer
1,308 -14.9%
1.39
US$1,818 		1,308 -14.9% 1.39 US$1,818
2023-08-07 2023-08-03 PlS Planned sale
1.4
Jordan Julie

Chief Medical Officer

Officer
109 -2.6%
1.39
US$152 		109 -2.6% 1.39 US$152
2023-08-07 2023-08-03 PlS Planned sale
1.4
Jordan Julie

Chief Medical Officer

Officer
436 -10.1%
1.39
US$606 		436 -10.1% 1.39 US$606
2023-08-04 2023-08-02 PlS Planned sale
1.4
Jordan Julie

Chief Medical Officer

Officer
99 -3.5%
1.31
US$130 		99 -3.5% 1.31 US$130
2023-03-06 2023-03-02 PlS Planned sale
Alloway Paul

See Remarks

Officer
10,965 -39.6%
1.45
US$15,863 		10,965 -39.6% 1.45 US$15,863
2023-01-11 2023-01-09 PlS Planned sale
TZIANABOS ARTHUR
Non-Executive Director
10,616 -8.9%
1.39
US$14,762 		10,616 -8.9% 1.39 US$14,762
2023-01-11 2023-01-09 PlS Planned sale
Alloway Paul

See Remarks

Officer
3,090 -13.3%
1.39
US$4,296 		3,090 -13.3% 1.39 US$4,296
2023-01-11 2023-01-09 PlS Planned sale
Blum Michael Lee

Chief Commercial Officer

Officer
2,454 -15.3%
1.39
US$3,412 		2,454 -15.3% 1.39 US$3,412
2023-01-11 2023-01-09 PlS Planned sale
Smith W Bradford

See Remarks

Officer
3,729 -20.8%
1.39
US$5,188 		3,729 -20.8% 1.39 US$5,188
2023-01-11 2023-01-09 PlS Planned sale
Seymour Albert

See Remarks

Executive Director
3,620 -2.5%
1.39
US$5,033 		3,620 -2.5% 1.39 US$5,033
2022-01-12 2022-01-05 PlS Planned sale
Cohn Gabriel

Chief Medical Officer

Officer
1,661 -38.7%
3.78
US$6,279 		1,661 -38.7% 3.78 US$6,279
2022-01-12 2022-01-05 PlS Planned sale
Smith W Bradford

CFO & Treasurer

Officer
2,182 -33.1%
3.78
US$8,248 		2,182 -33.1% 3.78 US$8,248
2022-01-12 2022-01-05 PlS Planned sale
Seymour Albert

Chief Scientific Officer

Officer
1,661 -1.2%
3.78
US$6,279 		1,661 -1.2% 3.78 US$6,279
2022-01-12 2022-01-05 PlS Planned sale
TZIANABOS ARTHUR

President & CEO

Executive Director
5,354 -5.9%
3.78
US$20,239 		5,354 -5.9% 3.78 US$20,239
2022-01-12 2022-01-05 PlS Planned sale
2.9
Kelly Timothy P

Chief Operating Officer

Officer
1,406 -38.7%
3.78
US$5,315 		1,406 -38.7% 3.78 US$5,315
2021-02-09 2021-02-08 PlS Planned sale
Smith W Bradford

CFO & Treasurer

Officer
13,500 -100.0%
14.25
US$192,425 		13,500 -100.0% 14.25 US$192,425
2021-02-05 2021-02-02 PlS Planned sale
2.9
Kelly Timothy P

See Remarks

Officer
500 -100.0%
13.00
US$6,500 		500 -100.0% 13.00 US$6,500
2021-02-03 2021-02-01 PlS Planned sale
2.9
Kelly Timothy P

See Remarks

Officer
4,000 -100.0%
12.37
US$49,460 		4,000 -100.0% 12.37 US$49,460
2021-01-14 2021-01-12 PlS Planned sale
2.9
Kelly Timothy P

See Remarks

Officer
500 -100.0%
13.00
US$6,500 		500 -100.0% 13.00 US$6,500
2021-01-08 2021-01-07 PlS Planned sale
Seymour Albert

Chief Scientific Officer

Officer
5,103 -3.8%
12.05
US$61,469 		5,103 -3.8% 12.05 US$61,469
2021-01-08 2021-01-06 PlS Planned sale
Seymour Albert

Chief Scientific Officer

Officer
9,897 -6.9%
12.06
US$119,395 		9,897 -6.9% 12.06 US$119,395
2021-01-07 2021-01-05 PlS Planned sale
Seymour Albert

Chief Scientific Officer

Officer
10,000 -6.5%
11.44
US$114,422 		10,000 -6.5% 11.44 US$114,422
2021-01-06 2021-01-04 PlS Planned sale
2.9
Kelly Timothy P

See Remarks

Officer
4,000 -100.0%
11.50
US$45,983 		4,000 -100.0% 11.50 US$45,983
2020-12-28 2020-12-22 S Sale
4.0
PARMAR KUSH
Non-Executive Director
20,000 -9.9%
12.82
US$256,400 		20,000 -9.9% 12.82 US$256,400
2020-12-28 2020-12-22 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
20,000 -9.9%
12.82
US$256,400 		20,000 -9.9% 12.82 US$256,400
2020-12-28 2020-12-22 S Sale
4.0
PARMAR KUSH
Non-Executive Director
480,000 -9.9%
12.82
US$6,153,600 		480,000 -9.9% 12.82 US$6,153,600
2020-12-28 2020-12-22 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
480,000 -9.9%
12.82
US$6,153,600 		480,000 -9.9% 12.82 US$6,153,600
2020-12-16 2020-12-14 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
13,703 -6.4%
11.88
US$162,792 		13,703 -6.4% 11.88 US$162,792
2020-12-16 2020-12-14 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
6,297 -2.8%
13.06
US$82,244 		6,297 -2.8% 13.06 US$82,244
2020-12-16 2020-12-14 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
328,862 -6.4%
11.88
US$3,906,881 		328,862 -6.4% 11.88 US$3,906,881
2020-12-16 2020-12-14 S Sale
4.0
PARMAR KUSH
Non-Executive Director
13,703 -6.4%
11.88
US$162,792 		13,703 -6.4% 11.88 US$162,792
2020-12-16 2020-12-14 S Sale
4.0
PARMAR KUSH
Non-Executive Director
6,297 -2.8%
13.06
US$82,244 		6,297 -2.8% 13.06 US$82,244
2020-12-16 2020-12-14 S Sale
4.0
PARMAR KUSH
Non-Executive Director
328,862 -6.4%
11.88
US$3,906,881 		328,862 -6.4% 11.88 US$3,906,881
2020-12-16 2020-12-14 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
151,138 -2.8%
13.06
US$1,973,998 		151,138 -2.8% 13.06 US$1,973,998
2020-12-16 2020-12-14 S Sale
4.0
PARMAR KUSH
Non-Executive Director
151,138 -2.8%
13.06
US$1,973,998 		151,138 -2.8% 13.06 US$1,973,998
2020-03-18 2020-03-17 PlS Planned sale
2.9
Kelly Timothy P

See Remarks

Officer
1,315 -100.0%
13.01
US$17,109 		1,315 -100.0% 13.01 US$17,109
2020-02-05 2020-02-03 PlS Planned sale
TZIANABOS ARTHUR

President & CEO

Executive Director
12,500 -13.9%
16.16
US$202,021 		12,500 -13.9% 16.16 US$202,021
2020-02-05 2020-02-03 PlS Planned sale
Smith W Bradford

CFO, Treasurer & Secretary
12,000 -100.0%
16.16
US$193,866 		12,000 -100.0% 16.16 US$193,866
2020-01-31 2020-01-30 S Sale
2.8
Flynn James E
Large shareholder
509,970 -100.0%
15.45
US$7,879,036 		509,970 -100.0% 15.45 US$7,879,036
2020-01-31 2020-01-29 S Sale
2.8
Flynn James E
Large shareholder
8,857 -1.7%
15.45
US$136,808 		8,857 -1.7% 15.45 US$136,808
2020-01-28 2020-01-28 S Sale
2.8
Flynn James E
Large shareholder
65,891 -11.3%
15.51
US$1,021,936 		65,891 -11.3% 15.51 US$1,021,936
2020-01-28 2020-01-27 S Sale
2.8
Flynn James E
Large shareholder
193,359 -24.9%
15.77
US$3,049,600 		193,359 -24.9% 15.77 US$3,049,600
2020-01-28 2020-01-24 S Sale
2.8
Flynn James E
Large shareholder
380,256 -32.8%
15.69
US$5,965,000 		380,256 -32.8% 15.69 US$5,965,000
2020-01-03 2020-01-02 PlS Planned sale
Smith W Bradford

CFO, Treasurer & Secretary
6,000 -100.0%
20.50
US$122,984 		6,000 -100.0% 20.50 US$122,984
2020-01-03 2020-01-02 PlS Planned sale
Seymour Albert

Chief Scientific Officer
9,133 -5.6%
20.50
US$187,216 		9,133 -5.6% 20.50 US$187,216
2020-01-03 2020-01-02 PlS Planned sale
TZIANABOS ARTHUR

President & CEO

Executive Director
12,500 -12.2%
20.50
US$256,191 		12,500 -12.2% 20.50 US$256,191
2019-12-27 2019-12-24 S Sale Flynn James E Large shareholder
151,233 -7.9%
21.95
US$3,319,579 		151,233 -7.9% 21.95 US$3,319,579
2019-12-27 2019-12-24 S Sale Flynn James E Large shareholder
198,767 -7.9%
21.95
US$4,362,956 		198,767 -7.9% 21.95 US$4,362,956
2019-12-23 2019-12-23 S Sale Flynn James E Large shareholder
56,595 -2.9%
21.83
US$1,235,435 		56,595 -2.9% 21.83 US$1,235,435
2019-12-23 2019-12-23 S Sale Flynn James E Large shareholder
74,384 -2.9%
21.83
US$1,623,758 		74,384 -2.9% 21.83 US$1,623,758
2019-12-23 2019-12-20 S Sale Flynn James E Large shareholder
9,130 -0.5%
21.50
US$196,297 		9,130 -0.5% 21.50 US$196,297
Explore more

More insider trading research around Q32 Bio Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America